CAR T cell therapy: Pathways of Resistance

Fiona Byrd


• Successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukaemia and other cancer types
• Trials resulted in rapid FDA approvals of anti-CD19 CAR T cell products for types of B cell lymphoma
• However, remissions will be brief in a substantial number of patients owing to poor CAR T cell persistence and/or cancer cell resistance resulting from antigen loss or modulation

Full Text:



  • There are currently no refbacks.